Skip to content

Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients

Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00532597
Enrollment
20
Registered
2007-09-20
Start date
2007-04-30
Completion date
2008-03-31
Last updated
2007-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease, Hemodialysis

Keywords

Vascular Endothelium-Dependent Relaxation, Hemodialysis, Hemodiafiltration

Brief summary

The purpose of this study is to determine whether on-line hemodiafiltration ameliorate the endothelial dysfunction compared with the low flux hemodialysis in end stage renal disease patients on maintenance hemodialysis.

Detailed description

1. On-line hemodiafiltration(OL-HDF) is a technique that combines diffusion with convection in which the large substitution fluid is produced directly from the dialysate. It offers many advantages aside from its safe inflammatory profile, which is attributable to the use of ultrapure dialysate and highly biocompatible dialysis membranes. Due to an improved convective clearance, significantly increased removal of large or protein-bound uremic retention solutes can be achieved, with a potential benefit on cardiovascular morbidity and mortality. 2. Endothelial dysfunction, almost universal in end stage renal disease, is important risk factor for cardiovascular events, and can be evaluated by brachial artery endothelium-dependent vasodilation (flow-mediated dilation) to reactive hyperemia following 5 min of forearm ischemia. 3. The stable HD patients will receive 8-week treatment on OL-HDF or conventional low flux HD and then crossed over to opposite treatment arm. The FMD will be measured by one sonographer, and at the same time whole blood and serum will be sampled and stored for further analysis. The timepoint for measurement is 4-week interval after baseline evaluation.

Interventions

Sponsors

Eulji General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* end stage renal disease on maintenance hemodialysis for more than 3 months

Exclusion criteria

* diagnosis of active cardiovascular diseases in 6 months * elevation of liver enzymes over two fold of upper normal limit in 3 months * admission for acute infection in 3 months * untreatable stenosis of vascular access

Design outcomes

Primary

MeasureTime frame
endothelial dysfunction measured by flow-mediated vasodilation4 months

Countries

South Korea

Contacts

Primary ContactYoung-Hwan Hwang, M.D.
ondahl@eulji.ac.kr82-2-970-8457
Backup ContactSu-Ah Sung, M.D., PhD.
soi@eulji.ac.kr82-2-970-8205

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026